JPH09510201A - 臨床的効用を有する二重特異性分子 - Google Patents
臨床的効用を有する二重特異性分子Info
- Publication number
- JPH09510201A JPH09510201A JP7523559A JP52355995A JPH09510201A JP H09510201 A JPH09510201 A JP H09510201A JP 7523559 A JP7523559 A JP 7523559A JP 52355995 A JP52355995 A JP 52355995A JP H09510201 A JPH09510201 A JP H09510201A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- specific
- effector
- target cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/086—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.標的細胞特異性リガンドとエフェクター細胞特異性抗体を含んでなる二重 特異性分子。 2.リガンドが腫瘍細胞の自己分泌増殖因子である請求の範囲1に記載の二重 特異性分子。 3.腫瘍細胞がヒト小細胞肺癌細胞である請求の範囲2に記載の二重特異性分 子。 4.リガンドがガストリン放出ペプチド受容体に結合する請求の範囲3に記載 の二重特異性分子。 5.リガンドが、ボンベシンとガストリン放出ペプチド、またはそれらの類似 体からなる群から選ばれる請求の範囲4に記載の二重特異性分子。 6.エフェクター細胞特異性抗体がエフェクター細胞のFc受容体に結合する 請求の範囲1に記載の二重特異性分子。 7.エフェクター細胞特異性抗体が、内因性免疫グロブリンによって阻害され ない部位でFcγ受容体に結合する請求の範囲6に記載の二重特異性分子。 8.Fcγ受容体が、FcγRI、FcγRIIおよびFcγRIIIからな る群から選ばれる請求の範囲7に記載の二重特異性分子。 9.エフェクター細胞特異性抗体が、mAb22、mAb32、mAb44、 mAb62およびmAb197からなる群から選ばれる請求の範囲8に記載の二 重特異性分子。 10.標的細胞特異性リガンドがボンベシンまたはその類似体であり、そして エフェクター細胞特異性抗体がヒトFcγRI特異性モノクロー ナル抗体である請求の範囲1に記載の二重特異性分子。 11.(i)標的細胞特異性リガンド、および (ii)エフェクター細胞に結合しているエフェクター細胞特異性抗体を含んで なる、標的細胞に対する抗体依存性エフェクター細胞仲介細胞毒性を誘発するた めの標的細胞特異性エフェクター細胞。 12.標的細胞が腫瘍細胞である請求の範囲11に記載の標的細胞特異性エフ ェクター細胞。 13.腫瘍細胞がヒト小細胞肺癌細胞である請求の範囲12に記載の標的細胞 特異性エフェクター細胞。 14.標的細胞特異性リガンドが、ヒト小細胞肺癌細胞の自己分泌増殖因子で ある請求の範囲13に記載の標的細胞特異性エフェクター細胞。 15.標的細胞特異性リガンドがボンベシンとガストリン放出ペプチド、およ びそれらの類似体からなる群から選ばれる請求の範囲14に記載の標的細胞特異 性エフェクター細胞。 16.エフェクター細胞のFc受容体が、FcγRI、FcγRIIおよびF cγRIIIからなる請求の範囲11に記載の標的細胞特異性エフェクター細胞 。 17.エフェクター細胞特異性抗体がmAb22、mAb32、mAb44、 mAb62およびmAb197からなる群から選ばれる請求の範囲16に記載の 標的細胞特異性エフェクター細胞。 18.薬学的に許容される媒体中の請求の範囲1、6、9または10に記載の 二重特異性分子を被験者に投与することを含んでなる、被験者中に、標的細胞に 対する特異性抗体依存性エフェクター細胞仲介性細胞毒性を誘発する方法。 19.標的細胞が腫瘍細胞である請求の範囲18に記載の方法。 20.腫瘍細胞がヒト小細胞肺癌細胞である請求の範囲19に記載の方法。 21.薬学的に許容される担体中の二重特異性分子特異性リガンドを被験者に 投与することを含んでなる被験者中の免疫反応を刺激する方法。 22.二官能分子の標的細胞特異性リガンドが自己分泌増殖因子であり、そし てエフェクター細胞特異性抗体がエフェクター細胞のFcγ受容体に対して特異 性がある請求の範囲21に記載の方法。 23.二官能分子の標的細胞特異性リガンドが、インスリン様増殖因子I、ト ランスフェリン、血管作用性腸菅ペプチド、ニューロテンシン、ニューロメジン B、ニューロフィシン、腫瘍壊死因子、トランスフォーミング増殖因子アルファ 、血小板由来増殖因子、トランスフェリン受容体およびそれらの類似体からなる 群から選ばれる請求の範囲22に記載の方法。 24.二官能分子の標的細胞特異性リガンドが、ボンベシンとガストリン放出 ペプチドまたはそれらの類似体からなる群から選ばれる請求の範囲23に記載の 方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20734494A | 1994-03-07 | 1994-03-07 | |
US08/207,344 | 1994-03-07 | ||
PCT/US1995/002750 WO1995024220A1 (en) | 1994-03-07 | 1995-03-07 | Bispecific molecules having clinical utilities |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09510201A true JPH09510201A (ja) | 1997-10-14 |
Family
ID=22770141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7523559A Pending JPH09510201A (ja) | 1994-03-07 | 1995-03-07 | 臨床的効用を有する二重特異性分子 |
Country Status (11)
Country | Link |
---|---|
US (3) | US5833985A (ja) |
EP (1) | EP0749325B1 (ja) |
JP (1) | JPH09510201A (ja) |
AT (1) | ATE218890T1 (ja) |
AU (1) | AU692239B2 (ja) |
CA (1) | CA2183268C (ja) |
DE (1) | DE69527050T2 (ja) |
DK (1) | DK0749325T3 (ja) |
ES (1) | ES2178669T3 (ja) |
PT (1) | PT749325E (ja) |
WO (1) | WO1995024220A1 (ja) |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6018031A (en) * | 1989-10-20 | 2000-01-25 | Trustees Of Dartmouth College | Binding agents specific for IgA receptor |
PT749325E (pt) * | 1994-03-07 | 2002-11-29 | Medarex Inc | Mpleculas biespecificas possuindo utilidades clinicas |
US6111166A (en) * | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
US7332168B2 (en) | 2000-08-22 | 2008-02-19 | Micromet Ag | Composition for the elimination of autoreactive B-cells |
JP4986370B2 (ja) | 2000-12-22 | 2012-07-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Rgmおよびそのモジュレーターの用途 |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
ES2552281T3 (es) | 2001-05-11 | 2015-11-26 | Ludwig Institute For Cancer Research Ltd. | Proteínas de unión específica y usos de las mismas |
WO2004039826A1 (en) | 2001-11-14 | 2004-05-13 | Centocor, Inc. | Anti-il-6 antibodies, compositions, methods and uses |
JP2005517025A (ja) | 2002-02-08 | 2005-06-09 | エクサイト セラピーズ, インコーポレイテッド | 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法 |
WO2003068822A2 (en) * | 2002-02-13 | 2003-08-21 | Micromet Ag | De-immunized (poly)peptide constructs |
EP1581648A2 (en) * | 2002-09-09 | 2005-10-05 | Nura, Inc. | G protein coupled receptors and uses thereof |
US20080260744A1 (en) * | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
DE10256042B4 (de) * | 2002-11-30 | 2006-06-08 | Universität Potsdam | Verfahren zur Selektion von Zellen, die spezifisch bindende Moleküle produzieren |
US20060239923A1 (en) * | 2003-01-13 | 2006-10-26 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
US7850947B2 (en) | 2003-01-13 | 2010-12-14 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
US7922998B2 (en) | 2003-01-13 | 2011-04-12 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
US7226577B2 (en) | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
US7611692B2 (en) | 2003-01-13 | 2009-11-03 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
US8420050B2 (en) | 2003-01-13 | 2013-04-16 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
US20080014594A1 (en) * | 2003-01-31 | 2008-01-17 | Kevin Hestir | Lung-Expressed Polypeptides |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
US8124085B2 (en) | 2004-05-05 | 2012-02-28 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
JP2008518947A (ja) * | 2004-10-29 | 2008-06-05 | エルシス セラピューティクス, インク. | 免疫応答のクリアランス及び誘導におけるcr1結合分子の使用 |
PE20061324A1 (es) | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
PT1896073E (pt) | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Composições, métodos e aplicações de anticorpos anti-il-23 |
ES2539250T3 (es) | 2005-07-25 | 2015-06-29 | Emergent Product Development Seattle, Llc | Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20 |
JP2009510002A (ja) | 2005-09-30 | 2009-03-12 | アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 反発誘導分子(rgm)タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用 |
MX2008008621A (es) | 2005-12-29 | 2008-11-27 | Centocor Inc | Anticuerpos anti-il-23 humanos, composiciones, metodos y usos. |
US9044461B2 (en) | 2006-04-07 | 2015-06-02 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
WO2007117657A2 (en) | 2006-04-07 | 2007-10-18 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
SG172698A1 (en) | 2006-06-12 | 2011-07-28 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function |
WO2008079849A2 (en) * | 2006-12-22 | 2008-07-03 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
WO2008091701A2 (en) | 2007-01-25 | 2008-07-31 | Dana-Farber Cancer Institute | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
MX2009009782A (es) | 2007-03-15 | 2010-09-10 | Ludwig Inst Cancer Res | Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas. |
CN108424454B (zh) | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
NZ586701A (en) | 2008-01-03 | 2013-07-26 | Scripps Research Inst | Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2) |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
EP2510001B1 (en) | 2009-12-08 | 2015-12-02 | AbbVie Deutschland GmbH & Co KG | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
EP2533810B1 (en) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
DK2552961T3 (en) | 2010-03-30 | 2018-03-05 | Janssen Biotech Inc | HUMANIZED IL-25 ANTIBODIES |
EP4269563A3 (en) | 2010-06-19 | 2024-01-10 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
CN103857699B (zh) | 2011-05-24 | 2016-08-31 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
AU2012352168C1 (en) | 2011-12-14 | 2018-01-25 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
US9636398B2 (en) | 2011-12-14 | 2017-05-02 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
PL2807192T3 (pl) | 2012-01-27 | 2019-02-28 | Abbvie Deutschland | Kompozycja oraz sposób diagnostyki i leczenia chorób związanych ze zwyrodnieniem neurytów |
CN105705165B (zh) | 2013-03-15 | 2020-04-24 | 纪念斯隆-凯特琳癌症中心 | 高亲和力抗gd2抗体 |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
WO2014197885A2 (en) | 2013-06-07 | 2014-12-11 | Duke University | Inhibitors of complement factor h |
CA2935378C (en) | 2013-12-24 | 2023-04-18 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
WO2016187068A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
US11009509B2 (en) | 2015-06-24 | 2021-05-18 | Janssen Pharmaceutica Nv | Anti-VISTA antibodies and fragments |
MY197562A (en) | 2015-09-21 | 2023-06-23 | Aptevo Res & Development Llc | Cd3 binding polypeptides |
CN116920085A (zh) | 2016-02-12 | 2023-10-24 | 詹森药业有限公司 | 抗-vista(b7h5)抗体 |
EP3436477A2 (en) | 2016-03-29 | 2019-02-06 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
WO2018045379A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
MA46366A (fr) | 2016-09-30 | 2019-08-07 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23 |
JP2019535015A (ja) | 2016-10-03 | 2019-12-05 | アボット・ラボラトリーズAbbott Laboratories | 患者サンプルにおけるgfap状況を評価する改善された方法 |
EP3541422A4 (en) | 2016-11-16 | 2020-05-06 | Janssen Biotech, Inc. | METHOD FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY |
WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
AU2017396503A1 (en) | 2017-01-30 | 2019-07-11 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Psoriatic arthritis |
AU2017398101A1 (en) | 2017-02-07 | 2019-08-01 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis |
WO2018175942A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
US10877048B2 (en) | 2017-04-15 | 2020-12-29 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
JP7080899B2 (ja) | 2017-04-28 | 2022-06-06 | アボット・ラボラトリーズ | 同じヒト対象に由来する少なくとも2つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法 |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
BR112019024701A2 (pt) | 2017-05-25 | 2020-06-09 | Abbott Lab | métodos para auxiliar na determinação se um exame de imagem deve ser realizado em um indivíduo humano que sofreu ou pode ter sofrido uma lesão na cabeça com o uso de biomarcadores precoces |
CA3059601A1 (en) | 2017-05-30 | 2018-12-06 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers |
US11169159B2 (en) | 2017-07-03 | 2021-11-09 | Abbott Laboratories | Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood |
WO2019113525A2 (en) | 2017-12-09 | 2019-06-13 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) |
JP7379165B2 (ja) | 2017-12-09 | 2023-11-14 | アボット・ラボラトリーズ | Gfapとuch-l1との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法 |
AU2019232624A1 (en) | 2018-03-05 | 2020-09-10 | Janssen Biotech, Inc. | Methods of treating Crohn's disease with anti-IL23 specific antibody |
MA52590A (fr) | 2018-05-11 | 2021-03-17 | Janssen Biotech Inc | Méthodes de traitement de la dépression à l'aide d'anticorps il-23 |
WO2019246494A1 (en) | 2018-06-21 | 2019-12-26 | Yumanity Therapeutics, Inc. | Compositions and methods for the treatment and prevention of neurological disorders |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
WO2020016838A2 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
CN113395979A (zh) | 2018-11-20 | 2021-09-14 | 詹森生物科技公司 | 用抗il-23特异性抗体治疗银屑病的安全且有效的方法 |
JP2022534020A (ja) | 2019-05-23 | 2022-07-27 | ヤンセン バイオテツク,インコーポレーテツド | Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 |
WO2020245677A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
EP4136459A1 (en) | 2020-04-13 | 2023-02-22 | Abbott Laboratories | Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample |
JP2023536737A (ja) | 2020-08-04 | 2023-08-29 | アボット・ラピッド・ダイアグノスティクス・インターナショナル・アンリミテッド・カンパニー | Sars-cov-2を検出するためのアッセイ |
WO2022031804A1 (en) | 2020-08-04 | 2022-02-10 | Abbott Laboratories | Improved methods and kits for detecting sars-cov-2 protein in a sample |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
CA3198161A1 (en) | 2020-12-01 | 2022-06-09 | Beth MCQUISTON | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
EP4271998A1 (en) | 2020-12-30 | 2023-11-08 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
KR20230156387A (ko) | 2021-03-12 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체에 의해 건선성 관절염을 치료하는 안전하고 효과적인 방법 |
CA3213278A1 (en) | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
AU2022279156A1 (en) | 2021-05-18 | 2023-11-02 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
AU2022293389A1 (en) | 2021-06-14 | 2024-01-04 | Abbott Laboratories | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
WO2023034777A1 (en) | 2021-08-31 | 2023-03-09 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
WO2023056268A1 (en) | 2021-09-30 | 2023-04-06 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US20230151087A1 (en) | 2021-11-15 | 2023-05-18 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
WO2023129942A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
US20230312703A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of Treating Psoriasis with IL-23 Specific Antibody |
WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5109115A (en) * | 1985-03-29 | 1992-04-28 | The United States Of America As Represented By The Secretary Of The Dept. Of Health & Human Services | Monoclonal antibody specific for bombesin |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4954617A (en) * | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
ES2096590T3 (es) * | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
ATE175118T1 (de) * | 1990-10-05 | 1999-01-15 | Medarex Inc | Gezielte immunostimulierung mit bispezifischen stoffen |
AU5322494A (en) * | 1992-10-02 | 1994-04-26 | Trustees Of Dartmouth College | Bispecific reagents for redirected targeting of low density lipoprotein |
PT749325E (pt) * | 1994-03-07 | 2002-11-29 | Medarex Inc | Mpleculas biespecificas possuindo utilidades clinicas |
-
1995
- 1995-03-07 PT PT95912740T patent/PT749325E/pt unknown
- 1995-03-07 WO PCT/US1995/002750 patent/WO1995024220A1/en active IP Right Grant
- 1995-03-07 CA CA002183268A patent/CA2183268C/en not_active Expired - Fee Related
- 1995-03-07 DK DK95912740T patent/DK0749325T3/da active
- 1995-03-07 DE DE69527050T patent/DE69527050T2/de not_active Expired - Fee Related
- 1995-03-07 AU AU19798/95A patent/AU692239B2/en not_active Ceased
- 1995-03-07 JP JP7523559A patent/JPH09510201A/ja active Pending
- 1995-03-07 ES ES95912740T patent/ES2178669T3/es not_active Expired - Lifetime
- 1995-03-07 EP EP95912740A patent/EP0749325B1/en not_active Expired - Lifetime
- 1995-03-07 AT AT95912740T patent/ATE218890T1/de not_active IP Right Cessation
- 1995-05-26 US US08/451,194 patent/US5833985A/en not_active Expired - Fee Related
-
2000
- 2000-12-12 US US09/735,173 patent/US20010005747A1/en not_active Abandoned
-
2005
- 2005-02-22 US US11/063,670 patent/US20050240012A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2178669T3 (es) | 2003-01-01 |
AU1979895A (en) | 1995-09-25 |
US20050240012A1 (en) | 2005-10-27 |
CA2183268C (en) | 2001-05-15 |
DK0749325T3 (da) | 2002-10-07 |
DE69527050D1 (de) | 2002-07-18 |
AU692239B2 (en) | 1998-06-04 |
PT749325E (pt) | 2002-11-29 |
DE69527050T2 (de) | 2003-02-13 |
US20010005747A1 (en) | 2001-06-28 |
US5833985A (en) | 1998-11-10 |
CA2183268A1 (en) | 1995-09-14 |
EP0749325A1 (en) | 1996-12-27 |
ATE218890T1 (de) | 2002-06-15 |
EP0749325B1 (en) | 2002-06-12 |
WO1995024220A1 (en) | 1995-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09510201A (ja) | 臨床的効用を有する二重特異性分子 | |
Traunecker et al. | Soluble CD4 molecules neutralize human immunodeficiency virus type 1 | |
AU667460B2 (en) | Targeted immunostimulation with bispecific reagents | |
AU2005270336B2 (en) | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent | |
Mittler et al. | T-cell receptor-CD4 physical association in a murine T-cell hybridoma: induction by antigen receptor ligation. | |
KR100667121B1 (ko) | 바이러스 감염증 치료를 위한 조성물 및 방법 | |
US6018031A (en) | Binding agents specific for IgA receptor | |
JPH09503511A (ja) | 細胞および血清タンパク質アンカー並びに接合体 | |
Keler et al. | Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fcγ receptor type I-expressing effector cells | |
US7226601B1 (en) | Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate | |
JP2005507870A (ja) | 低毒性のインターロイキン−2突然変異体 | |
CN108727504A (zh) | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 | |
KR102011789B1 (ko) | 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포 | |
JP2020143084A (ja) | 治療目的のための抗体−ウレアーゼコンジュゲート | |
US20210253713A1 (en) | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use | |
CZ43798A3 (cs) | Fúzní proteiny, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje | |
WO2018231661A1 (en) | Methods and reagents to treat tumor and cancer | |
Pietersz et al. | Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy | |
Scott Jr et al. | Human T cells can be directed to lyse tumor targets through the alternative activation/T11-E rosette receptor pathway. | |
WO2022022709A1 (zh) | 一种SIRPα-Fc融合蛋白 | |
Chen et al. | An immunoconjugate of Lys3-bombesin and monoclonal antibody 22 can specifically induce FcgammaRI (CD64)-dependent monocyte-and neutrophil-mediated lysis of small cell carcinoma of the lung cells | |
JP3109678B2 (ja) | アメリカやまごぼう抗ウイルス蛋白質―モノクローナル抗体コンジュゲート | |
WO2023174213A9 (zh) | 抗体药物偶联物及其应用 | |
Scott et al. | Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells. | |
EA042513B1 (ru) | Psma-нацеленные триспецифические белки и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060912 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070312 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081104 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090106 |